Abstract
The effect of ritanserin on dopamine (DA) re-uptake and efflux was studied in rat frontal cortex synaptosomes. When compared to other 5HT2 receptor antagonists such as ketanserin and risperidone or DA D2 receptor antagonists such as haloperidol and raclopride, the effect of ritanserin proved to be more potent. Ritanserin blocked the DA transporter with a Ki of 0.18 ± 0.06 μM, similar to cocaine (0.11 ± 0.005 μM), while ketanserin had a Ki of 0.93 ± 0.045; haloperidol of 2.07 ± 0.12; risperidone of 18.01 ± 0.62 and raclopride of 24.01 ± 1.55. In addition, 15 min from its local application to the synaptosomes, ritanserin potently released [3]H-DA leaving only 29.6 ± 1.6% of DA content, while ketanserin effect was equal to 46.5 ± 0.9%; haloperidol to 70.4 ± 2.2% and risperidone to 73.9 ± 1.5%, all tested at the dose of 10 μM. Cocaine had no effect on DA efflux. These results suggest that ritanserin has a intrinsic dopaminergic effect which may help to explain its reported improvement on mood, cognition and negative symptoms of schizophrenia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chiodo LA, Bunney BS . Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons J Neurosci 1983; 3: 1607–1619
Moghaddam B, Bunney BS . Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study J Neurochem 1990; 54: 1755–1760
Leysen JE, Jansenn PMF, Heylen L, Gommeren W, Van Gompel P, Lesage et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects Int J Psych Clin Pract 1998; 2: S3–S17
Leysen JE, Niemegeers CJEJ, Tollenaere JP, Laduron PM . Serotonergic component of neuroleptic receptors Nature 1978; 272: 168–171
Meltzer HY, Matsubara S, Lee JC . Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 1989; 251: 238–246
Leysen JE, Commeron W, Van Gompel P, Wynants J, Jansenn PMF, Laduron PM . Receptor-binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin S2 antagonist Mol Pharmacol 1985; 27: 600–611
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N . Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R-55667), a new selective 5-HT2 receptor blocking agent Curr Ther Res 1986; 40: 492–499
Gelders YG . Thymostenic agents, a novel approach in the treatment of schizophrenia Br J Psychiatry 1989; 155: 33–36
Ugedo L, Grenhoff J, Svensson TH . Ritanserin, a 5HT2 antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition Psychopharmacology 1989; 98: 45–50
Devaud LL, Hollingsworth EB, Cooper BR . Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin J Neurochem 1992; 59: 1459–1466
Pehek EA . Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat prefrontal cortex Synapse 1996; 24: 12–18
Lappalainen J, Hieatala J, Koulu M, Syvalahtti E . Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects Eur J Pharmacol 1990; 190: 403–407
Saller CF, Czupryna MJ, Salama AI . 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effect of D2 dopamine receptor blockade J Pharmacol Exp Ther 1990; 253: 1162–1170
Liebman JM, Gerhardt SC, Geber R . Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT–dopamine interaction Psychopharmacology (Berl) 1989; 97: 456–461
Guimarães FS, Mbaya PS, Deakin JFW . Ritanserin facilitates anxiety in a simulated public-speaking paradigm J Psychopharmacol 1997; 11: 225–231
Johnson BA, Chen YR, Swann AC, Schmitz J, Lesser J, Ruiz P et al. Ritanserin in the treatment of cocaine dependence Biol Psychiatry 1997; 42: 932–940
Tatsumi M, Jansen K, Blakely RD, Richelson E . Pharmacological profile of neuroleptics at human monoamine transporters Eur J Pharmacol 1999; 368: 277–283
Richelson E, Pfenning M . Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinefrine uptake Eur J Pharmacol 1984; 104: 277–286
Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P et al. Cloning and expression of a cocaine-sensitive dopamine transporter cDNA Science 1991; 254: 576–578
Amara SG, Kuhar MJ . Neurotransmitter transporters: recent progress Annu Rev Neurosci 1993; 16: 73–93
Sulzer D, Maidment NT, Rayport S . Amphetamine and other weak basis act to promote reverse transport of dopamine in ventral midbrain neurons J Neurochem 1993; 60: 527–535
Pehek EA, Bi Y . Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 671–682
Leysen JE, Van Gompel P, Verwimp M, Niemegeers CJ . Role and localization of serotonin2 (S2)-receptor-binding sites: effects of neuronal lesions Adv Biochem Psychopharmacol 1983; 37: 373–383
Fischette CT, Nock B, Renner K . Effects of 5,7,-dihydroxytriptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography Brain Res 1987; 421: 263–279
Araneda R, Andrade R . 5-Hydroxytryptamine2 and 5-Hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex Neuroscience 1991; 40: 399–412
Morilak DA, Garlow SJ, Ciaranello RD . Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain Neuroscience 1993; 54: 701–717
Hertel P, Nomikos G, Iurlo M, Svensson TH . Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain Psychopharmacology 1996; 124: 74–86
Greenhoff J, Tung CS, Ugedo L, Svensson TH . Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo Pharmacol Toxicol 1990; 66: (Suppl 1) 29–33
Weiberger DF . Implications of normal brain development for the pathogenesis of schizophrenia Arch Gen Psychiatry 1987; 44: 660–669
Leysen JE, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ . Biochemical profile of risperidone a new antipsychotic J Pharmacol Exp Ther 1988; 247: 661–670
Schoemaker H, Nickolson VJ . Dopamine uptake by rat striatal synaptosomes: time and temperature-dependent decay and protection by dithiothreitol and dopamine J Neurochem 1983; 40: 922–928
Acknowledgements
The present work was partially supported by the European Community, the Italian Government and the Regione Autonoma della Sardegna through the POP Sardegna.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruiu, S., Marchese, G., Saba, P. et al. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. Mol Psychiatry 5, 673–677 (2000). https://doi.org/10.1038/sj.mp.4000804
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4000804
Keywords
This article is cited by
-
One-pot synthesis, biological evaluation and molecular docking studies of fused thiazolo[2,3-b]pyrimidinone-pyrazolylcoumarin hybrids
Molecular Diversity (2018)
-
Benzo[h]thiazolo[2,3-b]quinazolines by an efficient p-toluenesulfonic acid-catalyzed one-pot two-step tandem reaction
Research on Chemical Intermediates (2016)
-
Treatment of Disorders of Hypersomnolence
Current Treatment Options in Neurology (2014)
-
Nicotinic–serotonergic drug interactions and attentional performance in rats
Psychopharmacology (2005)